ABPWW

Abpro Holdings, Inc. operates as a clinical-stage biotechnology company focused on developing antibody-based therapeutics for oncology and immunology applications. Headquartered in Woburn, Massachusetts, the company leverages its proprietary antibody discovery platforms to identify and advance novel therapeutic candidates targeting difficult-to-drug proteins and complex disease pathways. Abpro's pipeline includes multiple programs in preclinical and clinical development, with lead candidates designed to address significant unmet medical needs in cancer treatment. The company's core technology platforms enable the discovery of antibodies against challenging targets, including intracellular proteins and multi-pass membrane receptors that traditional approaches cannot effectively address. In July 2023, Abpro completed a business combination with Big Cypress Acquisition Corp., transitioning to publicly traded status on Nasdaq. The company maintains strategic partnerships with pharmaceutical organizations to advance its therapeutic programs and expand its technology applications. Abpro's research and development efforts focus on creating differentiated antibody therapeutics with potential best-in-class or first-in-class profiles. The company operates laboratory and office facilities in Massachusetts, where its scientific team conducts antibody discovery, optimization, and preclinical development activities. As a clinical-stage entity, Abpro has not yet generated product revenue and funds operations primarily through equity financing and partnership agreements.